SINGAPORE: Singapore reported nine new COVID-19 cases as of noon on Tuesday (Nov 10), said the Ministry of Health (MOH).
There were two locally transmitted infections, comprising one in the community and another in a dormitory.
The remaining seven cases were imported. They were placed on stay-home notice or isolated upon arrival in Singapore.
The new infections bring Singapore's tally of COVID-19 cases to 58,073.
READ: Singapore may enter Phase 3 before end of the year if ‘all the stars are aligned’: Lawrence Wong
LOCALLY TRANSMITTED CASES
The sole community case is currently unlinked. The man, a 25-year-old Malaysian, was last at work as a cleaner on Nov 2.
He developed symptoms a day later, and sought medical treatment at a General Practitioner clinic, where he was tested for COVID-19, MOH said.
There was also one case in the dormitory, who was detected through rostered routine testing of workers living in dormitories.
Among the imported cases, one is a Singaporean who returned from Uzbekistan and another is a Singapore permanent resident who returned from Indonesia.
Two cases are work permit holders who arrived from Indonesia.
The next case is a dependant’s pass holder who arrived from the United Arab Emirates.
The remaining two cases are short-term visit pass holders: A US man on a work project in Singapore, and the British spouse of a Singaporean who previously tested positive for COVID-19, MOH said.
NEW LOCATIONS ADDED TO PLACES VISITED BY COVID-19 CASES
MOH's report on Tuesday showed nine new entries added to a list of public places visited by COVID-19 cases in the community during their infectious period.
Bugis Street was visited three times between Nov 1 and Nov 8, while Kopitiam @ Jurong East was visited twice on Nov 6 and 8.
COVID-19 cases also visited Mustafa Centre on Nov 3, the Burger King outlet at Kitchener Complex on Nov 4 and Kopitiam at V Hotel Lavender on Nov 4, as well as Jurong Point on Nov 5.
Four more COVID-19 cases have been discharged from hospitals or community isolation facilities. This takes to 57,985 the total number of people who have fully recovered from the infection and have been discharged from hospitals or community care facilities, MOH said.
There are currently 40 confirmed cases still in hospital. Of these, most are stable or improving, and none is in the intensive care unit.
Twenty are isolated and cared for at community facilities. These are those who have mild symptoms, or are clinically well but still test positive for COVID-19.
The death toll from complications due to COVID-19 remains at 28.
READ: Any person or company who needs COVID-19 PCR test can get one at approved providers from Dec 1
PHASE 3 "CONTINGENT" ON PEOPLE DOING THEIR PART
Singapore may be able to enter Phase 3 before the end of the year “if all the stars are aligned”, said Minister for Education Lawrence Wong on Tuesday.
Responding to a question at a multi-ministry task force press conference on when Singapore may be able to enter Phase 3, Mr Wong said the timing will be "contingent” on individuals doing their part.
Singapore needs to see higher participation in the TraceTogether programme, as well as continued cooperation and compliance with all prevailing safe distancing measures, he added.
The authorities also announced that any company or person who requires a COVID-19 polymerase chain reaction (PCR) test will be able to get one at approved providers from Dec 1.
This includes individuals who need pre-departure testing before they travel. They no longer need to seek approval from MOH for these pre-departure tests, said Health Minister Gan Kim Yong.
READ: COVID-19 - About 25 nightspots to reopen under pilot scheme; business body urges others to pivot or exit
The health ministry also said travellers who are not Singaporeans or permanent residents entering Singapore from high-risk countries will need to take PCR test within 72 hours before their departure.
This is part of the country’s plans to reduce the risk of imported cases from high-risk countries and regions, said MOH.
Mr Gan added that MOH has set up an expert committee to advise on and assess the efficacy and safety of COVID-19 vaccines.
The committee will “closely monitor” vaccine clinical trials data and recommend vaccination approaches for different groups of people.